SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

TPOXX

SIGA·SIGA Technologies Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available (oral since 2018, IV since 2022).
Why 4/10
TPOXX is already FDA-approved and commercially marketed with no pending PDUFA or pivotal readout in the next ~12 months; the next hard catalyst is Q3 2026 earnings (Nov 5, 2026), which is a quarterly commercial update, not a binary drug-approval event. The planned FDA submission for PEP is targeted for H1 2027, over 6 months away. Per the rubric, an approved drug with no imminent regulatory binary scores 3-5.
Actionable Insight NEUTRAL

The next hard catalyst is Q3 2026 earnings on November 5, 2026, which will show whether TPOXX deliveries continued and whether management has secured a new multi-year BARDA procurement contract. Without a new contract, the revenue cliff from the nearly-exhausted 19C contract is the dominant risk. The longer-term catalyst is the planned FDA submission for post-exposure prophylaxis in H1 2027, but that is over six months away and not yet a binary event.

Price Chart

Loading chart...

Executive Summary

TPOXX (tecovirimat) is the only FDA-approved drug specifically indicated for treating smallpox, developed by SIGA Technologies (NASDAQ: SIGA). Approved orally in 2018 and intravenously in 2022, it is sold almost exclusively to governments for biodefense stockpiling, with the U.S. government (BARDA) as the dominant customer under a contract valued at up to $630M. The stock has fallen ~60% from its 52-week high as the BARDA contract nears exhaustion (~86% exercised), two mpox trials failed primary endpoints, and the EMA withdrew the mpox indication in March 2026. Q2 2026 revenue fell 49% YoY to $41M. The company is pursuing label expansion into post-exposure prophylaxis (FDA submission targeted H1 2027) and a pediatric formulation, but faces a revenue cliff without a new multi-year procurement contract.

How It Works

TPOXX is an antiviral that blocks the VP37 envelope-wrapping protein of orthopoxviruses (the family that includes smallpox, monkeypox/mpox, and cowpox). By inhibiting this protein, the drug prevents the virus from leaving infected cells and spreading to new cells in the body. It is taken as oral capsules or given intravenously for patients who cannot swallow.

Trial Status

TPOXX is FDA-approved for smallpox treatment in adults and pediatric patients weighing at least 13 kg (oral) or 3 kg (IV). Two Phase 3 mpox trials (PALM 007 and STOMP) failed to meet primary endpoints. The company is developing a pediatric oral suspension (Phase 1) and pursuing post-exposure prophylaxis (PEP) with an FDA submission targeted for H1 2027.

The Two-Sided Case

▲ Bull Case5
TPOXX is the only FDA-approved drug specifically indicated for smallpox, a critical biodefense asset stockpiled by the U.S. Strategic National Stockpile and over 30 countries (source: siga.com).
SIGA is targeting an FDA submission for post-exposure prophylaxis (PEP) in H1 2027, which could expand TPOXX's addressable market beyond treatment of active disease (source: seekingalpha.com).
The company has a strong patent portfolio with 26 U.S. utility patents and 101 issued foreign patents protecting TPOXX (source: stocklight.com).
Several institutional investors added or doubled positions in Q2 2026, including Morgan Stanley (+60%), Qube Research (+79%), and Jacobs Levy (+94%).
SIGA paid a $43M special dividend in early 2026, signaling management's willingness to return capital to shareholders (source: panabee.com).
▼ Bear Case5
~86% of the $630M BARDA 19C contract has already been exercised, leaving a thin revenue backlog and a looming revenue cliff (source: panabee.com).
Q2 2026 revenue fell 49% YoY to $41M and EPS dropped to $0.17 from $0.49; Q1 2026 revenue was just $6.2M, showing extreme quarter-to-quarter volatility (source: tradingkey.com).
Two major mpox trials (PALM 007 and STOMP) failed to meet primary endpoints, and the EMA recommended withdrawing the mpox indication for tecovirimat in March 2026, removing a key growth thesis (source: bioworld.com).
The company is a single-product, single-customer business: TPOXX is the only product and the U.S. government (BARDA) is the dominant buyer (source: seekingalpha.com).
Several tracked institutional investors trimmed or exited positions in Q2 2026, including Goldman Sachs (-37%), D.E. Shaw (-42%), and Florida Retirement System (-90%).

Upcoming Catalysts

  • Q3 2026 earnings report on November 5, 2026, which will reveal TPOXX delivery volumes and any update on new BARDA procurement contract
  • Potential new multi-year U.S. government procurement contract to replace the expiring 19C BARDA contract
  • FDA submission for post-exposure prophylaxis (PEP) targeted for first half of 2027
  • Phase 1 results for pediatric oral suspension formulation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

SIGA Technologies Inc. Press Release SIGA ·Originating report

Sources · 13

Hover a chip for the title
1 siga.com2 accessdata.fda.gov3 investor.siga.com4 tradingkey.com5 panabee.com6 bioworld.com7 seekingalpha.com8 seekingalpha.com9 investor.siga.com10 investor.siga.com11 stocklight.com12 panabee.com13 fda.gov